Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

Podcast

Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.

In a conversation with CancerNetwork® during March’s Myeloma Awareness Month, Krina Patel, MD, MSc, spoke about disparities in outcomes and clinical trial access for patients with multiple myeloma.

Patel, associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed previous research focusing on how factors including gender, race, and ethnicity correlated with treatment outcomes with autologous hemopoietic stem cell transplantation and CAR T-cell therapy.

She also detailed ongoing efforts from organizations such as the FDA and the International Myeloma Foundation on increasing enrollment of underserved patient groups on clinical trials as well as financial initiatives that may help to reduce barriers to treatment including transportation.

Don’t forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content